FY2025 · ended Dec 31, 2025 · Revenue $263.50M, +60.6% YoY · Filed Feb 24, 2026
Iovance Biotherapeutics, Inc. (IOVA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $263.5 million and a net loss of $391.0 million. Free cash flow was -$336.2 million. As of Sep 30, 2026 it held $376.3 million in cash and investments and $45.2 million in total debt.
Revenue (TTM)
$378.98M
+51.3% vs year-ago TTM
Net income (TTM)
$-220.53M
+44.5% vs year-ago TTM
Operating cash flow (TTM)
$-189.95M
+41.2% vs year-ago TTM
Free cash flow (TTM)
$-216.06M
+38.6% vs year-ago TTM
EPS
$-1.09
+14.8% vs prior year
Dividend per share
None
Shares outstanding
411.96M
+25.6% vs prior year
Net cash
$331.11M
as of Sep 30, 2026
Operating margin
-60.8%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IOVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1425205
- Former names
- Lion Biotechnologies, Inc. (until Jun 5, 2017); Genesis Biopharma, Inc (until Sep 23, 2013); FREIGHT MANAGEMENT CORP (until Mar 8, 2010)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | — | — |
| Operating income | -$403.4M | -$395.3M | -$460.6M | -$398.9M | -$342.7M |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M | -$342.3M |
| Diluted EPS | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 |
| Operating cash flow | -$302.4M | -$353.0M | -$361.8M | -$292.8M | -$227.9M |
| Free cash flow | -$336.2M | -$364.0M | -$384.1M | -$313.2M | -$265.5M |
| Total assets | $913.2M | $910.4M | $780.4M | $664.0M | $777.3M |
| Total liabilities | $214.6M | $200.0M | $195.7M | $164.3M | $155.7M |
| Stockholders' equity | $698.6M | $710.4M | $584.6M | $499.6M | $621.7M |
| Cash and investments | $297.0M | $323.8M | $279.9M | $471.8M | $596.0M |
| Total debt | $48.4M | $57.3M | $74.9M | $84.4M | $70.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 29, 2026 |
All 1003 Iovance Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.